3091192
Last Update Posted: 2025-05-14
Recruiting has ended
All Genders accepted | 18 Years-130 Years |
60 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Savolitinib vs. Sunitinib in MET-driven PRCC.
This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.
Eligibility
Relevant conditions:
Carcinoma
Carcinoma, Renal Cell
Kidney Neoplasms
Urologic Neoplasms
Kidney Diseases
Neoplasms by Site
Enzyme Inhibitors
Protein Kinase Inhibitors
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov